Minerva Neurosciences (NERV) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St mixed as investors assess softer jobs data
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Minerva Neurosciences (NERV) Annonuces Significant Top-Line Data from MDD with MIN-202 Phase 1b
March 11, 2016 8:33 AM ESTMinerva Neurosciences, Inc. (NASDAQ: NERV) announced positive top line results from a Phase Ib clinical trial in major depressive disorder (MDD) with MIN-202 (JNJ-42847922), a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV.
Treatment with MIN-202 was observed to result in consistent improvements in the symptoms of depression in MDD patients in this trial, said Dr. Remy Luthringer, president and chief executive officer of Minerva. The results pave the way to initiate a Phase IIb trial in patients suffering from MDD. These improvements support the potential of MIN-202 to have a... More
